赵永梅

赵永梅，女，汉族，1987.09，博士，硕士生导师，讲师

教育经历：

2006.09-2010.07         湘潭大学              化学         学士

2010.09-2013.07         山东大学             有机化学      硕士

2014.09-2017.12         昆士兰大学           药物制剂      博士

工作经历：

2018.12-至今  南通大学，药学院，讲师

研究方向：

药剂，纳米生物材料

社会学术兼职：

无

基金项目：

国家自然科学青年基金，82204319，靶向肝星状细胞的“隐身”基因递送系统用于肝纤维化的治疗研究 ，2023/01-2025/12，30万元，主持

科研成果：

近五年来，本课题组致力于纳米药物在肿瘤及肝纤维化治疗中的研究。我们通过整合仿生材料学、高分子化学、分子生物学以及组织与细胞形态学等多学科策略，探索这些疾病的创新治疗方法。我们的研究得到了国家自然科学基金青年科学基金的支持。

代表论文：

1. Kai Ding¹, Hailong Li¹, Qian Xu¹, Kaikai Wang¹,Yongmei Zhao¹*, Kaikai Wang¹*, Tianqing Liu²*. Real-Time Label-Free Three Dimensional Invasion Assay for Anti-Metastasis Drug Screening using Impedance Sensing.Front. Pharmacol 2024, 11

2. Yongmei Zhao^#, Yan Zhu^#, Kai Ding, Shanshan Li, Tianqing Liu. Biomimetic nanovesicle co delivery system impairs energy metabolism for cancer treatment.Journal of Nanobiotechnology2023, 21, 229.

3. Yongmei Zhao, Yuanlin Zheng, Yan Zhu, Kai Ding, Mengjiao Zhou, Tianqing Liu. Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.International Journal of Pharmaceutics2023, 636, 122844.

4. Yongmei Zhao, Yuanlin Zheng, Yan Zhu, Hongyun Li, Hongyan Zhu, Tianqing Liu. Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer.Journal of Nanobiotechnology 2022, 20 (1), 359.

5. Yongmei Zhao, Qiongxia Yang, Dong Liu, Tianqing Liu, Lingyan Xing. Neurotoxicity of nanoparticles: Insight from studies in zebrafish.Ecotoxicology and Environmental Safety 2022, 242, 113896.

6. Yongmei Zhao,Tianqing Liu, Aditya Ardana, Nicholas L. Fletcher, Zachary H. Houston, Idriss Blakey, and Kristofer J. Thurecht.Investigation of a Dual siRNA/Chemotherapy Delivery System for Breast Cancer Therapy.ACS Omega 2022, 7 (20), 17119-17127.

7. Yongmei Zhao, Yuanlin Zheng, Yan Zhu, Yi Zhang, Hongyan Zhu,Tianqing Liu, M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer,Pharmaceutics, 2021, 13(9), 1493-1505

8. Yongmei Zhao, Kaikai Wang, Yuanlin Zheng, Xiaobao Zeng, Yi Chieh Lim,Tianqing Liu. Co-delivery of Salinomycin and Curcumin for Cancer Stem Cell Treatment by Inhibition of Cell Proliferation, Cell Cycle Arrest, and Epithelial–Mesenchymal Transition.Frontiers in Chemistry. 2021, 8, 601649

9. Yongmei Zhao,Nicholas L. Fletcher,Anna Gemmell,Zachary H. Houston,Christopher B. Howard,Idriss Blakey,Tianqing Liu,Kristofer J. Thurecht. Investigation of the Therapeutic Potential of a SynergisticDelivery System through Dual Controlled Release of Camptothecin–Doxorubicin. Advanced Therapeutics, 2020, 1900202.

10. Yongmei Zhao,Zhao Wei, Lim Yi Chieh, Liu Tianqing.Salinomycin-Loaded Gold Nanoparticles for Treating Cancer Stem Cells by Ferroptosis-Induced Cell Death.Molecular Pharmaceutics, 2019, 16(6): 2532-2539.

11. Yongmei Zhao,Chen Gang, Meng Zhengjie, Gong Guangming, Zhao Wei, Wang Kaikai, Liu Tianqing.A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy,Drug Delivery, 2019, 26(1): 717-723.

12. Yongmei Zhao, Nicholas L. Fletcher, Tianqing Liu, Anna C. Gemmell, Zachary H. Houston, Idriss Blakey, Kristofer J. Thurecht. In vivo therapeutic evaluation of polymeric nanomedicines: effect of different targeting peptides on therapeutic efficacy against breast cancer,Nanotheranostics, 2018.8.24, 2(4): 360-370.

13. Yongmei Zhao, Zachary H. Houston, Joshua D. Simpson, Liyu Chen, Nicholas L. Fletcher, Adrian V. Fuchs, Idriss Blakey, Kristofer J. Thurecht. Using peptide aptamer targeted polymers as a model nanomedicine for investigating drug distribution in cancer nanotheranostics.Molecular Pharmaceutics. 2017, 14, 3539-3549.